These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 1729144)

  • 21. Pathophysiology, assessment, and treatment of Parkinson's disease.
    Tapper VJ
    Nurse Pract; 1997 Jul; 22(7):76-8, 80, 85 passim. PubMed ID: 9253016
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Controlled-release carbidopa/levodopa (CR) in parkinsonian patients with response fluctuations on standard levodopa treatment: clinical and pharmacokinetic observations.
    Deleu D; Jacques M; Michotte Y; Ebinger G
    Neurology; 1989 Nov; 39(11 Suppl 2):88-92; discussion 95. PubMed ID: 2685654
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease.
    Nyholm D; Nilsson Remahl AI; Dizdar N; Constantinescu R; Holmberg B; Jansson R; Aquilonius SM; Askmark H
    Neurology; 2005 Jan; 64(2):216-23. PubMed ID: 15668416
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacotherapy for Parkinson's disease.
    Chen JJ; Swope DM
    Pharmacotherapy; 2007 Dec; 27(12 Pt 2):161S-173S. PubMed ID: 18041936
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Reducing dosing frequency of carbidopa/levodopa: double-blind crossover study comparing twice-daily bilayer formulation of carbidopa/levodopa (IPX054) versus 4 daily doses of standard carbidopa/levodopa in stable Parkinson disease patients.
    Hinson VK; Goetz CG; Leurgans S; Fan W; Nguyen T; Hsu A
    Clin Neuropharmacol; 2009; 32(4):189-92. PubMed ID: 19620848
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparative study of selegiline plus L-dopa-carbidopa versus L-dopa-carbidopa alone in the treatment of Parkinson's disease.
    Brannan T; Yahr MD
    Ann Neurol; 1995 Jan; 37(1):95-8. PubMed ID: 7818264
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New and emerging strategies for improving levodopa treatment.
    Tolosa ES; Valldeoriola F; Martí MJ
    Neurology; 1994 Jul; 44(7 Suppl 6):S35-44. PubMed ID: 8047259
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Recent advances in the treatment of Parkinson's disease.
    Martocci RJ
    J Am Osteopath Assoc; 1975 Apr; 74(8):730-41. PubMed ID: 1092751
    [No Abstract]   [Full Text] [Related]  

  • 29. [Update on current care guidelines. Parkinson's disease].
    Reijo M; Atula S; Heikkinen E; Jaakkola MR; Pekka J; Keränen T; Martikainen K; Pekkonen E; Sotaniemi K;
    Duodecim; 2010; 126(19):2289-90. PubMed ID: 21086687
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Development and progression of motor fluctuations and side effects in Parkinson's disease: comparison of Sinemet CR versus carbidopa/levodopa.
    Goetz CG; Tanner CM; Gilley DW; Klawans HL
    Neurology; 1989 Nov; 39(11 Suppl 2):63-6; discussion 72-3. PubMed ID: 2586764
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Continuous dopaminergic stimulation by Duodopa in advanced Parkinson's disease: Efficacy and safety].
    Annic A; Devos D; Seguy D; Dujardin K; Destée A; Defebvre L
    Rev Neurol (Paris); 2009; 165(8-9):718-27. PubMed ID: 19150100
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Controlled-release levodopa/carbidopa. III: Sinemet CR5 treatment of response fluctuations in Parkinson's disease.
    Cedarbaum JM; Hoey M; Kutt H; McDowell FH
    Clin Neuropharmacol; 1988 Apr; 11(2):168-73. PubMed ID: 3378225
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Parcopa: a rapidly dissolving formulation of carbidopa/levodopa.
    Med Lett Drugs Ther; 2005 Jan; 47(1201):12. PubMed ID: 15706700
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Square-wave action dystonia in Parkinson's disease.
    van den Munckhof P; Lenz FA; Chase TN
    Mov Disord; 1998 Mar; 13(2):354-6. PubMed ID: 9539355
    [No Abstract]   [Full Text] [Related]  

  • 35. [Benefit of L-DOPA-without-DCI (decarboxylase inhibitor) therapy on wearing-off phenomenon in advanced stages of Parkinson's disease patients].
    Hironishi M; Miwa H; Kondo T
    No To Shinkei; 2002 Feb; 54(2):127-32. PubMed ID: 11889758
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Duopa--a carbidopa/levodopa enteral suspension for Parkinson's disease.
    Med Lett Drugs Ther; 2015 Aug; 57(1474):112. PubMed ID: 26218794
    [No Abstract]   [Full Text] [Related]  

  • 37. [Therapeutic strategies in Parkinson's disease].
    Shoulson I
    Arch Neurobiol (Madr); 1991; 54(6):277-81. PubMed ID: 1687429
    [No Abstract]   [Full Text] [Related]  

  • 38. [Current therapeutic approach in Parkinson disease].
    Przedborski S; Levivier M
    Rev Med Brux; 1992 Dec; 13(10):360-6. PubMed ID: 1480887
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Parkinson's disease: therapeutic choices and timing decisions in patient management. Interview by Wayne Kuznar.
    Stacy M
    Geriatrics; 1999 Oct; 54(10):44-9; quiz 50. PubMed ID: 10542860
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment of early Parkinson's disease.
    Pahwa R; Lyons KE
    Curr Opin Neurol; 2014 Aug; 27(4):442-9. PubMed ID: 24950010
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.